Reduced Immune Response After Intradermal Flu Shot in Eczema

Share this content:
Reduced Immune Response After Intradermal Flu Shot in Eczema
Reduced Immune Response After Intradermal Flu Shot in Eczema

MONDAY, Feb. 13, 2017 (HealthDay News) -- For patients with moderate/severe atopic dermatitis (AD), those colonized with Staphylococcus aureus have a reduced immune response to intradermal influenza vaccination, according to a study published online Feb. 13 in the Journal of Allergy and Clinical Immunology.

Donald Y.M. Leung, M.D., Ph.D., from National Jewish Health in Denver, and colleagues compared antibody responses to intradermal vaccination among patients with moderate/severe AD versus non-atopic participants in an open-label study conducted at five sites during the 2012 to 2013 influenza season. A total of 347 participants were included and followed for 28 days after vaccination.

The researchers found that seroprotection rates for influenza B, H1N1, and H3N2 did not differ between participants with AD and non-atopic participants receiving intradermal vaccination, or for participants with AD receiving intradermal and intramuscular vaccination. Compared to noncolonized participants with AD, those with S. aureus colonization experienced lower seroprotection and seroconversion rates and lower hemagglutination-inhibition titer geometric mean fold increase against influenza B and lower seroconversion rates against influenza H1N1 after intradermal, but not intramuscular, vaccination.

"Because most patients with AD are colonized with S. aureus, intramuscular influenza vaccination should be given preference in these patients," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »